SusitnAKAlaska Public Notices, Explained
Active Public meeting or hearing Public Notices

Pharmacy & Therapeutics Committee Meeting

What is this notice about?

The Alaska Department of Health's Pharmacy and Therapeutics Committee will meet online and by phone on Friday, November 20, 2026 at 8:00 a.m. to review the Preferred Drug List, the list of medicines the state's Medicaid program prefers to cover. The public, health care professionals and drug companies can send written material ahead of time or ask to speak during the meeting.

Why was this notice issued?

The Division of Health Care Services is sponsoring a meeting of the Pharmacy and Therapeutics Committee to address the Preferred Drug List.

What action is being taken?

Holding a teleconference-only committee meeting to review drug classes on the Preferred Drug List, and accepting written submissions and spoken public comment related to the agenda items.

Who is involved: Pharmacy and Therapeutics Committee; Department of Health, Division of Health Care Services; Prime Therapeutics (webinar host); pharmaceutical manufacturers; health care professionals; members of the public

How can the public respond?

Respond by Wed, Nov 18, 2026 10 days from today.

“Public submissions should be received no later than November 18, 2026 to allow inclusion in the meeting. Pharmaceutical manufacturer Clinical Submissions accepted until November 6, 2026 at 4:00pm AK local time.”

Ways to respond

What to include

Anyone sending material must include a conflict of interest form, found at https://health.alaska.gov/dhcs/Documents/pharmacy/forms/Alaska-Medicaid-Clinical-Coverage-Review-Request-Disclosure-Form.pdf. Drug manufacturers must use the Clinical Submission form. To speak at the meeting, send the host in the Chat: (1) your name and credentials, if any; (2) who you represent (company, self, organization, group); (3) the drug class you want to comment on; and (4) any conflict of interest disclosure, such as financial ties to the topic. Alaskan health care professionals not tied to industry may comment at the start of the meeting; industry representatives are called on during the matching drug class discussion and are limited to 3 minutes. Industry presentations must follow federal rules, and any misrepresentation will be reported to the U.S. Food and Drug Administration (FDA) Office of Prescription Drug Promotion. Speakers must disclose conflicts of interest before addressing the committee. The meeting is being recorded. Agendas are posted at https://health.alaska.gov/en/education/pdl-preferred-drug-list/.

Contact

Matthew Parrott
State of Alaska, Department of Health, Division of Health Care Services
matthew.parrott@alaska.gov
907.334.2425
4601 Business Park Blvd, Bldg K, Anchorage, AK 99503

Will there be public meetings?

  • Pharmacy and Therapeutics Committee meeting: Fri, Nov 20, 2026, 8:00 a.m. Alaska time
    Teleconference and online webinar only (Microsoft Teams)
    Register at https://events.teams.microsoft.com/event/5370d856-b685-44be-8dab-e68ce09ec3ad@34c95ba7-5ec6-4527-bc5e-b33b58104992 and you will receive a confirmation email with joining information. To join by phone, dial 1.844-730-9010 (Toll Free), Webinar ID: 474 976 582#

Key dates

  • Nov 6, 2026: Deadline for pharmaceutical manufacturer Clinical Submissions (4:00pm AK local time)
  • Nov 18, 2026: Deadline for public and health care professional written submissions to be received for inclusion in the meeting
  • Nov 18, 2026: Deadline to request disability accommodations from Matthew Parrott at 907.334.2425 (2:00 p.m.)
  • Nov 20, 2026: Pharmacy and Therapeutics Committee meeting at 8:00 a.m.

Original notice text

Notice of Public Meeting State of Alaska Department of Health Division of Health Care Services The Division will be sponsoring the following meeting to address the Preferred Drug List. Please note, this meeting will be available via teleconference only. See registration instructions at the bottom of the page. The Pharmacy and Therapeutics Committee will meet Friday, November 20, 2026 at 8:00 a.m. Agendas are posted on the Health Care Services Preferred Drug List Program Overview website https://health.alaska.gov/en/education/pdl-preferred-drug-list/. Any pharmaceutical manufacturer may submit unsolicited material related to the agenda items by utilizing the Clinical Submission form. Clinical Submissions will be accepted until November 6, 2026 at 4:00pm AK local time. Forms may be found at: https://health.alaska.gov/dhcs/Documents/pdl/Documents/AK_Submission_Request_Form_for_Pharmaceutical_Manufacturers.pdf Any member of the public, including health care professionals, may submit unsolicited may submit unsolicited material related to the agenda items by sending an email to doh.hcs.pharmacy.info@alaska.gov or via mail to 4601 Business Park Blvd, Bldg K, Anchorage, AK 99503. A conflict of interest form must accompany any submission and can be found at: https://health.alaska.gov/dhcs/Documents/pharmacy/forms/Alaska-Medicaid-Clinical-Coverage-Review-Request-Disclosure-Form.pdf Submissions should be received no later than November 18, 2026 to allow inclusion in the meeting. If you cannot join the webinar and would like to join via teleconference, please dial 1.844-730-9010 (Toll Free) Webinar ID: 474 976 582# Individuals with disabilities who need special accommodations in order to participate should contact Matthew Parrott at 907.334.2425 no later than 2:00 p.m., Wednesday, November 18, 2026. Public Teams Connection Instructions You are invited to a Prime Therapeutics webinar. When: November 20, 2026 08:00 AM Alaska Topic: AK P&T Committee Meeting Please register by clicking the link below: https://events.teams.microsoft.com/event/5370d856-b685-44be-8dab-e68ce09ec3ad@34c95ba7-5ec6-4527-bc5e-b33b58104992 After registering, you will receive a confirmation email containing information about joining the webinar. This meeting is being recorded. If you are a member of the public, a healthcare professional, or an industry representative and wish to provide public comment at the meeting today, please send the following information via the Chat function to the host: 1. Name and credentials (if applicable) 2. Who you are representing/affiliation(s)) (company, self, organization, group) 3. The drug class for which you wish to provide public comment 4. Any conflict of interest disclosure (i.e., financial affiliations with the topic you are presenting on) The Chair will call on pharmaceutical industry representatives during the appropriate class discussion. If you are an Alaskan healthcare professional (not affiliated with industry), the chair will provide an opportunity at the beginning of the meeting for comments. Note that while the CMS Open Payments database is used to identify potential conflicts of interest, it is the speaker's responsibility to disclose any conflicts of interest prior to addressing the committee. All industry presentations (limited to 3 min) must be consistent with Federal regulation; any misrepresentation of products discussed by pharmaceutical representatives will be reported to the FDA's Office of Prescription Drug Promotion. https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/opdp-regulatory-information Written comments for this meeting may be sent to Matt Parrott at matthew.parrott@alaska.gov.

This summary was written by an AI model (Claude) from the official notice text. This is general information, not legal advice. Always confirm deadlines and instructions in the official notice. Legal disclaimer.